Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.103.10
- Author:
Jingwei XIA
1
;
Yuzhong CHEN
1
;
Shaodi WEN
1
;
Xiaoyue DU
1
;
Bo SHEN
1
Author Information
1. The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Lung neoolasms;
Neutrophil-to-lymphocyte ratio;
Nomogram
- MeSH:
Aged;
Antibodies, Monoclonal, Humanized/therapeutic use*;
Antineoplastic Agents, Immunological/therapeutic use*;
Biomarkers/blood*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Female;
Humans;
Immunotherapy/methods*;
Inflammation/blood*;
Leukocyte Count;
Lung Neoplasms/pathology*;
Lymphocytes;
Male;
Middle Aged;
Neutrophils;
Predictive Value of Tests;
Prognosis;
Retrospective Studies;
Survival Analysis;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2021;24(9):632-645
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Lung cancer is the leading cause of cancer-related death, of which non-small cell lung cancer (NSCLC) is the most common type. Immune checkpoint inhibitors (ICIs) have now become one of the main treatments for advanced NSCLC. This paper retrospectively investigated the effect of peripheral blood inflammatory indexes on the efficacy of immunotherapy and survival of patients with advanced non-small cell lung cancer, in order to find strategies to guide immunotherapy in NSCLC.
METHODS:Patients with advanced non-small cell lung cancer who were hospitalized in The Affiliated Cancer Hospital of Nanjing Medical University from October 2018 to August 2019 were selected to receive anti-PD-1 (pembrolizumab, sintilimab or toripalimab) monotherapy or combination regimens. And were followed up until 10 December 2020, and the efficacy was evaluated according to RECIST1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were followed up for survival analysis. A clinical prediction model was constructed to analyze the predictive value of neutrophil-to-lymphocyte ratio (NLR) based on NLR data at three different time points: before treatment, 6 weeks after treatment and 12 weeks after treatment (0w, 6w and 12w), and the accuracy of the model was verified.
RESULTS:173 patients were finally included, all of whom received the above treatment regimen, were followed up for a median of 19.7 months. The objective response rate (ORR) was 27.7% (48/173), the disease control rate (DCR) was 89.6% (155/173), the median PFS was 8.3 months (7.491-9.109) and the median OS was 15.5 months (14.087-16.913). The chi-square test and logistic multi-factor analysis showed that NLR6w was associated with ORR and NLR12w was associated with ORR and DCR. Further Cox regression analysis showed that NLR6w and NLR12w affected PFS and NLR0w, NLR6w and NLR12w were associated with OS.
CONCLUSIONS:In patients with advanced non-small cell lung cancer, NLR values at different time points are valid predictors of response to immunotherapy, and NLR <3 is often associated with a good prognosis.
